LLY

986.52

+0.18%↑

JNJ

242.2

+0.25%↑

ABBV

221.84

+0.98%↑

NVS

154.3

+0.79%↑

AZN

191.47

+0.72%↑

LLY

986.52

+0.18%↑

JNJ

242.2

+0.25%↑

ABBV

221.84

+0.98%↑

NVS

154.3

+0.79%↑

AZN

191.47

+0.72%↑

LLY

986.52

+0.18%↑

JNJ

242.2

+0.25%↑

ABBV

221.84

+0.98%↑

NVS

154.3

+0.79%↑

AZN

191.47

+0.72%↑

LLY

986.52

+0.18%↑

JNJ

242.2

+0.25%↑

ABBV

221.84

+0.98%↑

NVS

154.3

+0.79%↑

AZN

191.47

+0.72%↑

LLY

986.52

+0.18%↑

JNJ

242.2

+0.25%↑

ABBV

221.84

+0.98%↑

NVS

154.3

+0.79%↑

AZN

191.47

+0.72%↑

Home・Akciju saraksts・Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Atvērts

SektorsVeselības aprūpe

72.6 2.08

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

71.12

Max

72.7

Galvenie mērījumi
By Trading Economics
Ienākumi	-100M -229M
Pārdošana	46M 203M
Peļņas marža	-112.808
Darbinieki	1,402
EBITDA	4.7B 4.6B

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+34.2% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 29. apr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-1.3B 12B
Iepriekšējā atvēršanas cena	70.52
Iepriekšējā slēgšanas cena	72.6

Ziņu noskaņojums

By Acuity

50%

133 / 351 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Neutral Evidence

29.78 / 33.645 Atbalsts un pretestība

Ionis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 15. marts 21:14 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: Central Bank Decisions -2-

2026. g. 15. marts 21:14 UTC

Galvenie ziņu notikumi

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

2026. g. 16. marts 00:00 UTC

Galvenie ziņu notikumi

Hack on U.S. Medical Company Shows Reach of Iran's Cyber Capabilities -- WSJ

2026. g. 15. marts 23:45 UTC

Tirgus saruna

Nikkei May Decline on Concerns About Prolonged Middle East Conflict -- Market Talk

2026. g. 15. marts 23:44 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Falls as Rising Energy Prices Exacerbate Inflation Worries -- Market Talk

2026. g. 15. marts 23:35 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Rise on Supply Disruption Concerns -- Market Talk

2026. g. 15. marts 23:00 UTC

Iegādes, apvienošanās, pārņemšana

Micron Completes Acquisition Of PSMC's Tongluo P5 Site In Taiwan >MU

2026. g. 15. marts 22:37 UTC

Tirgus saruna

March Rate Hike Would Distance RBA From Government's May Budget -- Market Talk

2026. g. 15. marts 22:18 UTC

Tirgus saruna

RBA's Likely Hike Motivated By Inflation, Not Middle East -- Market Talk

2026. g. 15. marts 22:14 UTC

Peļņas

Genscript Biotech 2025 Adj Net $230.35M Vs. Adj Net $59.83M>1548.HK

2026. g. 15. marts 22:14 UTC

Peļņas

Genscript Biotech: 2025 Loss Due to High Base Effect, One-off Unrealized Gains Seen Last Year >1548.HK

2026. g. 15. marts 22:14 UTC

Peļņas

Genscript Biotech 2025 Rev $959.53M Vs. $594.49M >1548.HK

2026. g. 15. marts 22:14 UTC

Peļņas

Genscript Biotech 2025 Loss $532.83M Vs. Net $2.96B >1548.HK

2026. g. 15. marts 22:14 UTC

Peļņas

Genscript Biotech: 2025 Rev Supported by Substantial Increase in License Revenue>1548.HK

2026. g. 15. marts 22:00 UTC

Galvenie ziņu notikumi

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

2026. g. 15. marts 22:00 UTC

Galvenie ziņu notikumi

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

2026. g. 15. marts 03:00 UTC

Galvenie ziņu notikumi

For Xi, Iran War Reinforces View of U.S. as Dangerous Superpower -- WSJ

2026. g. 14. marts 15:00 UTC

Galvenie ziņu notikumi

Iran War Delivers Windfall to America's Oil Country -- WSJ

2026. g. 14. marts 02:03 UTC

Peļņas

This Copper Stock Is Worth Mining for Profits -- Barrons.com

2026. g. 14. marts 01:32 UTC

Iegādes, apvienošanās, pārņemšana

Bill Ackman's Pershing Square IPO Is Back On -- Barrons.com

2026. g. 14. marts 00:29 UTC

Iegādes, apvienošanās, pārņemšana

13D Filings -- Barrons.com

2026. g. 13. marts 22:27 UTC

Tirgus saruna

Galvenie ziņu notikumi

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

2026. g. 13. marts 22:13 UTC

Tirgus saruna

Galvenie ziņu notikumi

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

2026. g. 13. marts 22:04 UTC

Tirgus saruna

Galvenie ziņu notikumi

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

2026. g. 13. marts 22:00 UTC

Iegādes, apvienošanās, pārņemšana

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

2026. g. 13. marts 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 13. marts 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Financial Services Roundup: Market Talk

2026. g. 13. marts 20:02 UTC

Tirgus saruna

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

2026. g. 13. marts 19:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

2026. g. 13. marts 19:35 UTC

Galvenie ziņu notikumi

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Ionis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

34.2% augšup

Prognoze 12 mēnešiem

Vidējais 95.54 USD 34.2%

Augstākais 110 USD

Zemākais 72 USD

Pamatojoties uz 14 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Ionis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

14 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 14 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Ionis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

29.78 / 33.645Atbalsts un pretestība

The bullish and bearish events are balanced.

All events are bullish.

All events are bearish.

Noskaņojums

By Acuity

133 / 351 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.